EyePoint’s bid to compete with Eylea falls flat

EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT} dropped 70% when markets opened ...